Ludwig Institute For Cancer Research Ltd – Developmental Therapeutics Review – Q1 2011

Date: March 1, 2011
Pages: 87
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: L0FA1D1A16AEN
Leaflet:

Download PDF Leaflet

Ludwig Institute For Cancer Research Ltd – Developmental Therapeutics Review – Q1 2011
Ludwig Institute For Cancer Research Ltd - Developmental Therapeutics Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Ludwig Institute For Cancer Research Ltd - Developmental Therapeutics Review - Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope
  • Review of therapeutics under development by Ludwig Institute For Cancer Research Ltd.
  • Overview of products under development across various therapy areas.
  • Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Ludwig Institute For Cancer Research Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of Ludwig Institute For Cancer Research Ltd’s therapeutic products in the last quarter.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify new drug targets and therapeutic classes in Ludwig Institute For Cancer Research Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
  • Evaluate Ludwig Institute For Cancer Research Ltd’s position with total access to a detailed information on its therapeutic products development.
  • Assess the growth potential of Ludwig Institute For Cancer Research Ltd in its therapy areas of focus.
  • Exploit collaboration and partnership opportunities with Ludwig Institute For Cancer Research Ltd.
  • Avoid Intellectual Property Rights related issues.
Table of Contents
List of Tables
List of Figures
Ludwig Institute For Cancer Research Ltd Snapshot
Ludwig Institute For Cancer Research Ltd Overview
Key Information
Key Facts
Ludwig Institute For Cancer Research Ltd – Research and Development Overview
Key Therapeutic Areas
Ludwig Institute For Cancer Research Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ludwig Institute For Cancer Research Ltd – Pipeline Products Glance
Ludwig Institute For Cancer Research Ltd – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ludwig Institute For Cancer Research Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ludwig Institute For Cancer Research Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ludwig Institute For Cancer Research Ltd – Drug Profiles
Adriamycin + Cyclophosphamide + Vincristine + Methotrexate + Fluorouracil
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Methotrexate + Fluorouracil + Prednisone
Product Description
Mechanism of Action
R&D Progress
177LU-DOTA-CG250
Product Description
Mechanism of Action
R&D Progress
177LU-DOTA-CG250
Product Description
Mechanism of Action
R&D Progress
8 HLA-A2 RESTRICTED PEPTIDES + MONTANIDE ISA-51
Product Description
Mechanism of Action
R&D Progress
ADI PEG 20
Product Description
Mechanism of Action
R&D Progress
Anti-CTLA4 (monoclonal antibody MDX-010)
Product Description
Mechanism of Action
R&D Progress
KW2871 + interferon-alfa2b
Product Description
Mechanism of Action
R&D Progress
Lutetium-177 Labeled cG250
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 ISCOMATRIX + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 ISCOMATRIX vaccine
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 ISCOMATRIX vaccine + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 Protein Vaccine + Poly-ICLC + Montanide ISA-51
Product Description
Mechanism of Action
R&D Progress
124I-HUA33
Product Description
Mechanism of Action
R&D Progress
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine + Sargramostim
Product Description
Mechanism of Action
R&D Progress
Capecitabine + 131I-huA33
Product Description
Mechanism of Action
R&D Progress
CH806
Product Description
Mechanism of Action
R&D Progress
CHP-HER2 + CHP-NY-ESO-1 + OK-432
Product Description
Mechanism of Action
R&D Progress
huA33 + 5-Fluorouracil (5FU) + Leucovorin + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Melan-A Analog Peptide + CpG 7909 + Montanide ISA-51
Product Description
Mechanism of Action
R&D Progress
Melan-A Analog Peptide + FluMa Peptide + Mage-A10 Peptide
Product Description
Mechanism of Action
R&D Progress
Melan-A Analog Peptide + Tyrosinase peptide + CpG 7909 + Montanide ISA-51
Product Description
Mechanism of Action
R&D Progress
Melan-A Natural Peptide + CpG 7909 + Montanide ISA-51
Product Description
Mechanism of Action
R&D Progress
Melan-A Natural Peptide + Tyrosinase peptide + CpG 7909 + Montanide ISA-51
Product Description
Mechanism of Action
R&D Progress
Mixed Bacterial Vaccine
Product Description
Mechanism of Action
R&D Progress
Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide
Product Description
Mechanism of Action
R&D Progress
Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide
Product Description
Mechanism of Action
R&D Progress
Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + IL-2
Product Description
Mechanism of Action
R&D Progress
Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide
Product Description
Mechanism of Action
R&D Progress
Montanide + Melan-A analogue peptide
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 + CpG 7909
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 + CpG 7909 + Montanide
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 OLP4 + Montanide
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 OLP4 + Montanide + Poly-ICLC
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 Overlapping Peptides
Product Description
Mechanism of Action
R&D Progress
Yttrium-90 conjugated chimeric G250
Product Description
Mechanism of Action
R&D Progress
Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide
Product Description
Mechanism of Action
R&D Progress
Ludwig Institute For Cancer Research Ltd – Pipeline Analysis
Ludwig Institute For Cancer Research Ltd – Pipeline Products by Therapeutic Class
Ludwig Institute For Cancer Research Ltd - Pipeline Products By Target
Ludwig Institute For Cancer Research Ltd – Pipeline Products by Route of Administration
Ludwig Institute For Cancer Research Ltd – Pipeline Products by Molecule Type
Ludwig Institute For Cancer Research Ltd - Dormant Projects
Ludwig Institute For Cancer Research Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Ludwig Institute For Cancer Research Ltd, Deals Volume Summary, 2004 to YTD 2011
Ludwig Institute For Cancer Research Ltd, Deals Summary By Region, 2004 to YTD 2011
Ludwig Institute For Cancer Research Ltd, Deals Summary, 2004 to YTD 2011
Ludwig Institute For Cancer Research Ltd Detailed Deal Summary
Serametrix Enters Into An Agreement With Ludwig Institute for Cancer Research
Morphotek Enters Into Research Agreement With Ludwig Institute for Cancer Research
Genaera Extends Collaboration Agreement With Ludwig Institute for Cancer Research
Licensing Agreements
CureVac Enters Into Licensing Agreement With Ludwig Institute For Cancer Research
Celldex Therapeutics Enters Into Licensing Agreement With Ludwig Institute
GlaxoSmithKline Enters Into Licensing Agreement With Ludwig Institute for Cancer Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Ludwig Institute For Cancer Research Ltd – Pipeline by Therapy Area and Indication, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline by Stage of Development, 2011
Ludwig Institute For Cancer Research Ltd – Monotherapy Products in Pipeline, 2011
Ludwig Institute For Cancer Research Ltd – Combination Treatment Modalities in Pipeline, 2011
Ludwig Institute For Cancer Research Ltd – Phase III, 2011
Ludwig Institute For Cancer Research Ltd - Phase II, 2011
Ludwig Institute For Cancer Research Ltd - Phase I, 2011
Ludwig Institute For Cancer Research Ltd - Pipeline By Therapeutic Class, 2011
Ludwig Institute For Cancer Research Ltd - Pipeline By Target, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline By Route of Administration, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline By Molecule Type, 2011
Ludwig Institute For Cancer Research Ltd - Dormant Developmental Projects, 2010
Ludwig Institute For Cancer Research Ltd, Other Locations
Ludwig Institute For Cancer Research Ltd, Deals Summary, 2004 to YTD 2011
Ludwig Institute For Cancer Research Ltd, Deals Summary by Region, 2004 to YTD 2011
Ludwig Institute For Cancer Research Ltd, Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Ludwig Institute For Cancer Research Ltd – Pipeline by Therapy Area and Indication, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline by Stage of Development, 2011
Ludwig Institute For Cancer Research Ltd – Monotherapy Products in Pipeline, 2011
Ludwig Institute For Cancer Research Ltd – Combination Treatment Modalities in Pipeline, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline By Therapeutic Class, 2011
Ludwig Institute For Cancer Research Ltd - Pipeline By Target, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline By Route of Administration, 2011
Ludwig Institute For Cancer Research Ltd – Pipeline By Molecule Type, 2011

Ask Your Question

Ludwig Institute For Cancer Research Ltd – Developmental Therapeutics Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: